Tumor Regulation of Lymph Node Lymphatic Sinus Growth and Lymph Flow in Mice and in Humans

Lauren M. Habenicht\textsuperscript{a,b}, Sara B. Kirschbaum\textsuperscript{c}, Momoko Furuya\textsuperscript{a}, Maria I. Harrell\textsuperscript{c,d}, and Alanna Ruddell\textsuperscript{a,c,e,*}

\textsuperscript{a}Department of Comparative Medicine, University of Washington, Seattle, WA; \textsuperscript{b}Harvard Center for Comparative Medicine, Harvard Medical School, Boston, MA; \textsuperscript{c}Fred Hutchinson Cancer Research Center, Seattle, WA; \textsuperscript{d}Department of Obstetrics and Gynecology, University of Washington, Seattle, WA; \textsuperscript{e}Department of Comparative Medicine, University of Washington School of Medicine, Seattle, WA

The lymphatic vasculature collects and drains fluid and cells from the periphery through lymph nodes (LNs\textsuperscript{†}) for immune monitoring, and then returns lymph to the bloodstream. During immune responses LNs enlarge and remodel, featuring extensive growth of lymphatic sinuses (lymphangiogenesis). This LN lymphangiogenesis also arises in cancer, and is associated with altered lymph drainage through LNs. Studies of mouse solid tumor models identified lymphatic sinus growth throughout tumor-draining LNs (TDLNs), and increased lymph flow through the expanded sinuses. Mice developing B cell lymphomas also feature LN lymphangiogenesis and increased lymph flow, indicating that these changes occur in lymphoma as well as in solid tumors. These LN alterations may be key to promote tumor growth and metastasis to draining LNs and distant organs. Lymphatic sinus growth within the TDLN may suppress anti-tumor-immune responses, and/or the increased lymph drainage could promote metastasis to draining LNs and distant organs. Investigations of human cancers and lymphomas are now identifying TDLN lymphatic sinus growth and increased lymph flow, that correlate with metastasis and poor prognosis. Pathology assessment of TDLN lymphangiogenesis or noninvasive imaging of tumor lymph drainage thus could potentially be useful to assist with diagnosis and treatment decisions. Moreover, the expanded lymphatic sinuses and increased lymph flow could facilitate vaccine or drug delivery, to manipulate TDLN immune functioning or to treat metastases. The insights obtained thus far should encourage further investigation of the mechanisms and consequences of TDLN lymphatic sinus growth and lymph flow alterations in mouse cancer models, and in human cancer patients.

\footnotesize*To whom all correspondence should be addressed: Alanna Ruddell, Department of Comparative Medicine, University of Washington School of Medicine, 1959 NE Pacific St., Box 357340, Seattle, WA 98195. Phone: 206-685-1216, Fax: 206-685-3006, Email: ruddella@uw.edu.

\footnotesize†Abbreviations: BEC, blood endothelial cell; DMBA/TPA, 7,12-Dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate; FRC, fibroreticular cell; HEV, high endothelial venule; LEC, lymphatic endothelial cell; LN, lymph node; LV, lymphatic vessel; MRI, magnetic resonance imaging; MHC, major histocompatibility complex; PD-L1, programmed death ligand-1; SMA, smooth muscle actin; TDLN, tumor-draining LN; VEGF, vascular endothelial growth factor; WT, wild-type.

Keywords: tumor-draining lymph node, lymphangiogenesis, lymph flow, cancer, lymphography, lymphatic endothelium

Author Contributions: LH, experimental design, analysis, and writing (NCI R01 CA68328); SK, experimental design and statistical analysis (NCI R01 CA68328); MF, experimental design and analysis (NCI R01 CA68328); MH, experimental design and statistical analysis (NCI R01 CA68328); AR, experimental design, analysis, and writing (grant NCI R01 CA68328 and FHCRC/UW Cancer Consortium Cancer Center Support Grant NIH NCI 5 P30 CA015704).
INTRODUCTION

The lymphatic vasculature serves to drain fluid, molecules, and cells from tissues for return to the blood circulation via thoracic duct delivery of lymph into the pulmonary vein [1,2]. Lymph is first taken up by blind-ended initial lymphatic vessels (LVs) that join to form muscle-coated collecting lymphatic vessels, which connect to a series of draining lymph nodes (LN) as the lymph returns to the heart. Within LNs the lymph is sampled by immune cells including lymphocytes, subcapsular macrophages, and dendritic cells, in order to encounter antigens and generate immune responses [3]. LNs enlarge and undergo extensive remodeling during immune responses to bacterial [4] or viral antigens [5], involving lymphocyte accumulation and proliferation of stromal components including lymphatic endothelial cells (LEC), fibroreticular cells (FRC), and blood endothelial cells (BEC) [6]. Within weeks the LN B cells form germinal centers, while T cells are activated to generate an adaptive immune response. At 5 to 10 days after the initial activation stage LN lymphatic sinus growth becomes prominent, continuing for over a month after infection [7]. Similar hypertrophy, lymphocyte accumulation, and lymphangiogenesis are features of tumor-draining lymph nodes (TDLNs) [8], and of LNs draining arthritic joints in autoimmune disease [9].

While the functional significance of LN lymphangiogenesis is not yet known, it has been proposed to suppress continuation of immune responses that could be deleterious [10,11]. In support of this idea, LN lymphatic endothelium can present antigens in a non-productive manner, to prevent T lymphocyte activation or survival [12-14]. However, it remains to be determined whether the increased LN lymphatic sinususes arising late in infections, or in autoimmune disease do contribute to suppression of immune responses. The expanded LN lymphatic sinus network could additionally promote delivery of antigens to the LN to reinforce peripheral tolerance, and/or to drain accumulated fluid and cell debris generated by inflammation. In cancer, the suppression of self or tumor antigen responses could block TDLN anti-tumor immune responses [15,16], although the requirement for lymphatic sinus growth in this process has not yet been investigated. Nonetheless, studies thus far provide evidence that TDLN lymphatic sinus growth and/or altered lymph drainage may be key to control tumor growth and metastasis. In this review we will discuss the TDLN lymphatic sinus and lymph drainage alterations and consequences that have been identified thus far in mouse models of cancer, and will compare these findings with reports of similar TDLN alterations in humans with cancer.

TOPICS

Lymph Node Lymphatic Sinus Growth in Murine Cancers

Naïve murine lymph nodes from young wild-type (WT) mice in specific pathogen-free animal facilities exhibit sparse lymphatic sinususes arranged around the outer margins of the cortex and medulla [17]. The medulla and cortex each comprise roughly half of the LN, surrounding the central T cell paracortex, as illustrated in Figure 1a. In normal 6 week-old mice, the subcapsular purple-staining lymphatic sinus surrounding the cortex of normal young mice is thin (Figure 1b; arrow), and cortical sinuses are not detected. In contrast, the medullary lymphatic sinuses are more developed (Figure 1b; arrowhead). Afferent lymphatic vessels (LVs) deliver lymph into the subcapsular and cortical sinuses, and then into the medullary sinususes that drain lymph to the efferent LV. As the immune system matures the lymphatic sinus network becomes more prominent, and mice develop primary B cell follicles and germinal centers in the cortex, while the medulla and paracortex mainly harbor T lymphocytes.

LN lymphatic sinus growth (lymphangiogenesis) has now been identified in the TDLNs of a variety of mouse models of cancer (Table 1). Both the cortical and medullary sinuses can grow and extend centrally into the B and T cell regions, respectively [18,19]. These changes are restricted to the TDLN but not non-draining LNs, indicating that they are induced by tumor lymph drainage [18]. TDLN lymphatic sinus growth has been identified in mice bearing melanoma or nasopharyngeal carcinoma cell line implants in the footpad that drain to the popliteal LN [18,19]. In lung carcinoma cell line implants in the flank, lymphangiogenesis is induced in draining and non-draining inguinal and axillary LNs [20]. Polyoma middle T antigen transgenic mice developing metastatic mammary carcinoma also developed generalized LN lymphangiogenesis [20]. Squamous cell carcinomas induced by DMBA chemical mutagenesis and TPA tumor promotion caused extensive LN lymphangiogenesis [21]. Lymphatic sinus growth throughout LNs was also detected in young preneoplastic E-\(\mu\)-c-myc mice (Figure 1c), even before the generation of metastatic B cell lymphomas [22]. In these mice, B lymphocyte accumulation throughout the LN drives extensive lymphatic sinus growth, so that the cortex and medulla cannot be distinguished (Figure 1c). These examples demonstrate that LN lymphangiogenesis is a feature of both solid tumors and lymphomas at early stages of tumor formation.

The development of LN lymphangiogenesis consistently preceded detection of tumor metastasis to the TDLN in solid tumor models (Table 1). Sensitive PCR assays did not identify melanoma cells in TDLNs exhibiting lymphangiogenesis [23], suggesting that these changes are me-
mediated by tumor antigens or signals rather than by delivery of tumor cells into the LN. Outbred mice developing benign papillomas after DMBA/TPA carcinogen and tumor promoter treatment showed modest TDLN lymphangiogenesis, while mice whose lesions transformed to form invasive and metastatic carcinomas exhibited much more extensive lymphatic sinus growth [21]. In addition, p19 Arf- or p53-tumor suppressor-deficient mice that rapidly progress to form invasive carcinomas exhibited extensive lymphangiogenesis at the benign papilloma stage, before conversion to invasive and metastatic carcinomas. VEGF-A- [24] or VEGF-C-overexpressing mice [25] developing DMBA/TPA-induced carcinomas also exhibited growth of tumor LVs and LN lymphatic sinuses, which were also associated with increased metastasis to LNs. VEGF-C treatment also promoted LN lymphatic sinus growth and metastasis of Lewis Lung Carcinoma cell line implants [20]. Taken together, these findings suggest that LN lymphatic sinus growth precedes and predicts the generation of metastatic tumors.

Lymph Node Lymphatic Endothelial Modulation of Adaptive Immune Responses

LN lymphatic endothelial cells (LEC) can generate and present a variety of peripheral tissue antigens via major histocompatibility complex (MHC) class I, and this has been proposed to reinforce peripheral immune tolerance [12,26]. These LEC do not express co-stimulatory molecules such as CD80/86 required for T cell activation, while they do express inhibitory ligands such as programmed death ligand-1 (PD-L1) so that engaged CD8 lymphocytes may instead be suppressed or deleted [3,16,27]. LN LEC can also cross-present tumor antigens obtained from the lymph [13,28] or from dendritic cells [29] on MHC class II to promote CD4 suppression [30]. LN LEC can additionally produce immunosuppressive molecules such as nitric oxide in vitro, which could also promote a tolerant microenvironment within the LN [31,32]. The fibroreticular cells (FRC) that coat conduit fibers within LNs [33,34] also present subsets of peripheral tissue antigens [26], and contribute nonproductive antigen presentation and nitric oxide production in vitro [31]. These and other studies suggest that the TDLN LEC (and FRC) can promote the generation of an immunosuppressive environment [16,35,36]. However, the effects of TDLN remodeling and of lymphangiogenesis on T and B lymphocyte immune responses have not yet been investigated in vivo. The consequences for LN responses to lymph-derived tumor antigens versus self antigens also remain to be distinguished in vivo.

B Lymphocyte Regulation of Tumor-draining Lymph Node Lymphatic Sinus Growth

B lymphocytes appear to be key for generation of LN lymphangiogenesis during immune responses [4,5,10]. In E-μ-c-myc transgenic mice, accumulation and spread of c-Myc-expressing B cells through the LNs of young preneoplastic mice [22] is associated with rapid lymphatic sinus growth throughout the LNs, so that the normal cortical and medullary anatomy is obscured (Figure 1c). Accumulation of B cells is required for lymphatic sinus growth in TDLNs of wild-type (WT) mice developing...
B16-F10 melanoma, as TDLN lymphatic sinuses fail to grow in B cell-deficient mice [18]. Interestingly, in the DMBA/TPA squamous cell carcinoma model, the extent of B cell accumulation predicts the extent of TDLN lymphangiogenesis, and also the potential to form invasive and metastatic carcinomas [21]. These findings suggest that B lymphocytes are a critical determinant of TDLN lymphangiogenesis and of metastasis. In support of this idea, implantation of melanoma and lymphoma cells into preneoplastic E-µ-c-myc mice featuring B lymphocyte accumulation and LN lymphangiogenesis greatly increased metastasis via the lymphatics to draining LNs, and then through the bloodstream to distant organs [23]. Tumor growth also modestly increased in these short-term tumor models. The effects of B lymphocytes on tumor growth and metastasis could involve downstream effects of the lymphatic sinus growth in E-µ-c-myc mice to promote immune tolerance, although this question has not yet been investigated. One study thus far has reported that introduced T lymphocytes inhibit LN lymphatic sinus growth after introduction into T cell-deficient nude mice [37]. It remains to be determined how B and T lymphocytes coordinate the extensive lymphangiogenesis that is observed in the B cell cortex and also in the T cell paracortex during immune responses [10] or in TDLNs [38].

Taken together, the studies thus far suggest that B lymphocytes are required to drive TDLN lymphangiogenesis [18], and that the growth of these lymphatic sinuses predicts tumor metastatic potential (Table 1) preceding significant metastasis to LNs [23]. Moreover, LNs featuring lymphangiogenesis promote growth and metastasis of lymphomas and melanomas to draining LNs and distant organs [23]. These findings suggest the hypothesis that TDLN lymphatic sinus growth actively promotes tumor dissemination, so that lymphangiogenesis could provide a critical target for therapeutic intervention to block metastasis. Further studies are required to directly test and identify the role of LN lymphangiogenesis in tumor dissemination. As LN LEC have been proposed to suppress anti-tumor immune responses [15,27], it will be particularly interesting to determine the effect of TDLN lymphatic sinus growth on the anti-tumor immune response.

**Molecules Regulating Lymph Node Lymphatic Sinus Growth**

A number of factors have been identified that can promote the growth of LVs, and the best characterized include vascular endothelial growth factor (VEGF)-A, -C, and -D [39,40]. It has been difficult to study the direct effects of lymphatic growth factors on TDLN lymphatic sinuses, as these same growth factors can also promote tumor-associated LV growth. Moreover, VEGF-A promotes growth of the tumor blood vasculature, which

---

**Table 1. Examples of lymph node lymphangiogenesis in mouse models of cancer.**

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Method of Tumor Induction</th>
<th>Key Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cell lymphoma</td>
<td>E-µ-c-myc transgenic mouse</td>
<td>LN lymphangiogenesis increases lymph flow and precedes generation of metastatic lymphoma</td>
<td>[22]</td>
</tr>
<tr>
<td>Lung Carcinoma</td>
<td>Lewis lung carcinoma cell line</td>
<td>LN lymphangiogenesis precedes metastasis</td>
<td>[20]</td>
</tr>
<tr>
<td>Mammary Carcinoma</td>
<td>Polyoma middle T antigen transgenic mouse</td>
<td>LN lymphangiogenesis precedes metastasis</td>
<td>[20]</td>
</tr>
<tr>
<td>Melanoma</td>
<td>B16-F10 cell line</td>
<td>B cells drive TDLN lymphangiogenesis and increase lymph flow before metastasis</td>
<td>[18]</td>
</tr>
<tr>
<td>Nasopharyngeal carcinoma</td>
<td>CNE-2 cell line</td>
<td>Tumors induce TDLN lymphangiogenesis</td>
<td>[19]</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>DMBA-TPA-induced</td>
<td>B cell accumulation and LN lymphangiogenesis precede and predict invasive carcinoma</td>
<td>[21]</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>DMBA-TPA-induced</td>
<td>Tumor VEGF-A overexpression increases LN lymphangiogenesis before and after metastasis</td>
<td>[24]</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>DMBA-TPA-induced</td>
<td>Tumor VEGF-C overexpression increases LN lymphangiogenesis and increases metastasis</td>
<td>[25]</td>
</tr>
</tbody>
</table>

---
can also induce LN lymphangiogenesis and promote tumor metastasis. An mCLCA1 LEC surface protein has been found to promote rapid lymphatic sinus growth that may be induced by lymphocyte LFA-1 binding to mCLCA1 [45,46], so that LN lymphatic sinus growth may be influenced by multiple pathways. Further studies will also be required to identify the critical regulators of TDLN lymphangiogenesis, and to determine whether these factors act through direct effects on the lymphatic sinus-

is required for tumor growth [41]. Nonetheless, evidence has been obtained that forced B cell expression of VEGF-A promotes LN lymphatic sinus growth [42], and c-Myc-expressing B cells express increased VEGF-A that is associated with LN lymphangiogenesis in E-µ-c-myc mice [22]. Tumor VEGF-A [24] or VEGF-C expression at high levels [25] both promote tumor-draining LV and LN lymphatic sinus growth. Erythropoietin treatment [43] or cyclooxygenase-2 production of prostaglandin E₂ [44] can also induce LN lymphangiogenesis and promote tumor metastasis. An mCLCA1 LEC surface protein has been found to promote rapid lymphatic sinus growth that may be induced by lymphocyte LFA-1 binding to mCLCA1 [45,46], so that LN lymphatic sinus growth may be influenced by multiple pathways. Further studies will also be required to identify the critical regulators of TDLN lymphangiogenesis, and to determine whether these factors act through direct effects on the lymphatic sinus-

**Figure 2. Lymph drainage through lymphatic sinuses of tumor-draining lymph nodes.** B16-F10 tumors were injected in one rear footpad of 5-week-old C57Bl/6J mice and grown for 3 weeks. Some mice (panels a-f) were anesthetized and injected in both dorsal toes with Texas Red dextran (Lysine-fixable 10,000 MW) to label the popliteal LN lymph drainage for 20 min before euthanasia (n = 9), while other mice were not injected with dextran (panels g,h). The lymphatic sinuses of the draining popliteal LNs were examined by immunostaining paraformaldehyde-fixed cryosections with 10.1.1 antibody (green). A small amount of Texas Red dextran is confined to the green lymphatic sinuses in the NTDLN (a). In the TDLN, much larger amounts of dextran are identified in the expanded green lymphatic sinuses (b). The white dashed boxes outline cortical regions shown at higher magnification in (c) and (d), while the outlined solid white boxes outline medullary regions shown at higher magnification in (e) and (f). Texas Red dextran is largely confined to the subcapsular and cortical lymphatic sinuses of the NTDLN (c) and TDLN (d). In the medulla, Texas Red dextran is largely confined to the sinuses, and is greatly increased in TDLNs (f), relative to the NTDLN (e). Red perlecan and green LYVE-1 lymphatic sinus immunostaining and Deltavision microscope imaging (Applied Biosciences) of the paracortex region adjacent to the medulla (g) identifies perlecan fibers surrounding lymphatic sinuses (L), high endothelial venules (H), capillaries, and conduits (arrows). Green perlecan immunostaining in combination with red SMA-1 immunostaining of FRCs (h) identifies the conduits of the paracortex (arrows). Scale bars for each image are 50 µm.
docyanine green [56,57] or near infrared nanoparticles [18,58] through LVs and LNs. Magnetic resonance imaging (MRI) using low molecular weight gadolinium [59] or nanoparticle-based gadolinium contrast [60,61] has been useful to provide high resolution images of lymph drainage through LVs and LNs of anesthetized mice. The LN lymphatic sinuses themselves have been indirectly visualized in vivo by optical imaging using fluorescent LYVE-1 antibody [62] or lymphatic sinus-binding LyP-1 peptide [63], although the images are of low resolution. Positron emission tomography using radio-labelled LYVE-1 antibody can also be used to obtain low resolution images to measure LN lymphatic sinus content in vivo [64]. In human cancer patients, lymphoscintigraphy using radioactive sulfur colloidal nanoparticles and visible Isosulfan Blue dye is commonly used for low resolution imaging of lymph drainage to identify the first (sentinel) TDLN, for biopsy and pathology analysis of LN metastasis [65,66].

### Imaging Lymph Drainage Through Lymph Nodes

The lymphatic circulation can be mapped by subcutaneous injection of India Ink [47], as these carbon nanoparticles of 20 to 70 nm diameter are taken up by LNs within minutes [48,49]. In fact, initial lymphatic vessels readily acquire molecules up to 70 nm diameter from the interstitium after subcutaneous injection [50-52]. Similarly, LNs rapidly filter the lymph upon entry to the subcapsular lymphatic sinuses, retaining molecules larger than ~40 to 70 kD while allowing smaller molecules to enter the conduits, as detected by microscopy of LN sections obtained from mice subcutaneously injected with these tracers [49,53] or by intravital microscopy in vivo [54,55]. Lymph drainage can also be visualized in vivo at lower resolution, using digital video cameras to grossly detect uptake of near infrared dyes such as docyanine green [56,57] or near infrared nanoparticles [18,58] through LVs and LNs.

Magnetic resonance imaging (MRI) using low molecular weight gadolinium [59] or nanoparticle-based gadolinium contrast [60,61] has been useful to provide high resolution images of lymph drainage through LVs and LNs of anesthetized mice. The LN lymphatic sinuses themselves have been indirectly visualized in vivo by optical imaging using fluorescent LYVE-1 antibody [62] or lymphatic sinus-binding LyP-1 peptide [63], although the images are of low resolution. Positron emission tomography using radio-labelled LYVE-1 antibody can also be used to obtain low resolution images to measure LN lymphatic sinus content in vivo [64]. In human cancer patients, lymphoscintigraphy using radioactive sulfur colloidal nanoparticles and visible Isosulfan Blue dye is commonly used for low resolution imaging of lymph drainage to identify the first (sentinel) TDLN, for biopsy and pathology analysis of LN metastasis [65,66].

Figure 3. Lymph node lymph flow increases in reneoplastic E-µ-c-myc mice. Near infrared imaging of 52 nm diameter quantum dots (800 nm emission, Invitrogen) using a Xenogen IVIS CCD camera, 10 min after injecting 25 microliters of quantum dots into the dorsal rear toe of the right leg of 6-week-old WT (a) or E-µ-c-myc mouse (b), draining to the popliteal LN (arrows). c. Total fluorescence efficiency was measured in a region of interest drawn over the popliteal LN of each mouse and pre-injection fluorescence efficiency of the same region of interest was subtracted at each time point. Standard errors are shown. Differences between WT and E-µ-c-myc mice at each time point are statistically significant by Mann-Whitney test (N = 10; *, p < 0.05; **, p < 0.01).
Some of the lymph in LN lymphatic sinuses enters tiny conduits in the B and T cell regions that connect to HEVs [49,68]. These conduits deliver antigens to dendritic cells coating the conduits, and to lymphocytes associated with HEVs [54,55]. Interestingly, the lymphatic sinuses filter lymph before entry to the conduits, as only molecules smaller than ~40 to 70 kD can be detected within the conduits [49,53]. The conduits are distributed throughout the parenchyma of LNs [49], and they can be identified at high magnification by immunostaining for the perlecan matrix component (arrows, Figure 2g). Perlecan also coats the much larger lymphatic sinuses (Figure 2g; L) and HEVs (Figure 2g; H) [55]. The conduits are coated with FRC that express smooth muscle actin (SMA) [55], as illustrated by perlecan/SMA immunostaining in Figure 2h (arrows). While low molecular weight dextran within conduits can be weakly detected in the LN parenchyma within 20 min after injection [49,55], we were unable to detect much if any fluorescent dye in the conduits or in the parenchyma adjacent to the cortical and medullary sinuses of normal or inflamed LNs harvested 5 min after injection [49]. Intravital microscopy of normal LNs of anesthetized mice identified transient transport of lymph-derived dextran through the conduits within the first min after injection, with the bulk of the injected dextran entering and persisting within the LN lymphatic sinuses mediates this increased lymph delivery to TDLNs [67], as illustrated by injection of fluorescent dextran (10,000 MW lysine-fixable Texas Red dextran, Sigma) into both dorsal toes of mice bearing B16-F10 melanoma in one rear footpad before euthanasia and immunostaining of LN cryosections (Figure 2). Nearly all of the Texas Red dextran was confined to the 10.1.1 Ab-stained cortical and medullary lymphatic sinuses (Figure 2a). Even with the greatly increased dextran uptake in TDLNs, the majority of lymph was confined to the lymphatic sinuses for at least 20 min after injection (Figure 2b). This is also evident in high magnification images of the LN parenchyma adjacent to the cortical and medullary sinuses of TDLNs (Figure 2c, e) and of TDLNs (Figure 2d, f).

Increased Lymph Flow Through Tumor-draining Lymph Nodes

Mice bearing B16-F10 footpad melanoma tumors have been useful to compare tumor-induced lymph flow through the TDLN versus the uninvolved contralateral popliteal NTDLN within the same mouse [18]. Injection of small numbers of melanoma cells into the footpad generate small tumors of 3 to 7 mm diameter that grow slowly and do not inhibit locomotion or visibly affect mouse behavior through about 21 days [18]. Xenogen IVIS imaging of 52 nm diameter near infrared quantum dots (800 nm; Invitrogen) injected into the dorsal toes of anesthetized mice identified greatly increased lymph flow through the TDLN, and very little drainage in the NTDLN [18]. Fluorescence microscopy determined that the extensive growth of lymphatic sinuses mediates this increased lymph delivery to TDLNs [67], as illustrated by injection of fluorescent dextran (10,000 MW lysine-fixable Texas Red dextran, Sigma) into both dorsal toes of mice bearing B16-F10 melanoma in one rear footpad before euthanasia and immunostaining of LN cryosections (Figure 2). Nearly all of the Texas Red dextran was confined to the 10.1.1 Ab-stained cortical and medullary lymphatic sinuses (Figure 2a). Even with the greatly increased dextran uptake in TDLNs, the majority of lymph was confined to the lymphatic sinuses for at least 20 min after injection (Figure 2b). This is also evident in high magnification images of the LN parenchyma adjacent to the cortical and medullary sinuses of TDLNs (Figure 2c, e) and of TDLNs (Figure 2d, f).
lymphatic sinuses over time [54,55]. Thus, while the conduit lymph drainage may facilitate local antigen presentation to lymphocytes and dendritic cells in the B and T cell regions [54,55], the conduits do not appear to physically contribute much lymph drainage relative to the large increase in lymphatic sinus lymph delivery into TDLNs.

**Increased Lymph Drainage in Lymphoma**

E-µ-c-myc transgenic mice exhibit LN hypertrophy [69] featuring B cell accumulation and extensive lymphatic sinus growth throughout the LNs (Figure 1c) at early preneoplastic stages, before the formation of metastatic B cell lymphomas [22]. LNs from these mice also exhibit increased lymph drainage through the lymphatic sinuses, as determined by subcutaneous TRITC dextran injection and imaging cryosections of the draining popliteal LNs after euthanasia [22]. This increased LN lymph flow was confirmed using Xenogen IVIS optical imaging after subcutaneous injection of near infrared quantum dots into the rear dorsal toes of anesthetized WT (Figure 3a) and E-µ-c-myc mice (Figure 3b). Measurement of the quantum dot uptake in the popliteal LN identified a six-fold increase in E-µ-c-myc mice within a minute after injection and continuing over 10 minutes, which was statistically significant (Figure 3c). The mechanism increasing lymph flow into the LNs of E-µ-c-myc mice remains to be determined. The afferent (arrows) and efferent (arrowheads) lymphatic vessels of WT (Figure 4a) and E-µ-c-myc littermates (Figure 4b) are of similar size and morphology, as illustrated by Evan’s Blue dye injection [70] and photography of the inguinal fatpad in necropsies, except that there is much more dye uptake in the LNs and LN of E-µ-c-myc mice (Figure 4b). This increased lymph drainage is also not associated with growth of LVs in the injected foot [23]. However, E-µ-c-myc B cell c-Myc overexpression within the LNs has multiple effects on transcription and translation [71] that could potentially influence lymphatic functions, such as VEGF-A production [72].

Our findings that the major changes in the vascular-
contrast is largely confined to the cortical margins of normal LNs [67], where the sinuses are transporting lymph (Figure 2a). Interestingly, TDLNs showed strong gadolinium contrast uptake into the medullary sinuses [67], which likely reflects the increased lymph flow through the expanded medullary lymphatic sinuses (Figure 2b). This increased contrast uptake in the medullary sinuses could also make a useful biomarker for non-invasive imaging of TDLN lymphangiogenesis and increased lymph flow, as medullary sinus lymphangiogenesis is a common feature of TDLNs [83].

One caveat of the use of lymphography to map lymph drainage to TDLNs is that murine tumors can sometimes block or divert lymph drainage. Aggressive tumor growth requires rapid formation of an abnormal blood vasculature that includes LVs [84]. High tumor interstitial pressure can divert or block lymph drainage through peritumoral LVs [85,86], and metastasis to LNs can also block lymph drainage [87,88]. Diverted or blocked lymph drainage is also sometimes observed in human cancer patients [85], which complicates the use of lymphography to correctly identify the sentinel or first tumor-draining LN [89,90].

**Tumor-draining Lymph Node Lymphangiogenesis and Increased Lymph Flow in Human Cancers**

These initial findings from studies of mouse cancer models support a key role of TDLN lymphatic sinus growth, and possibly also of increased lymph drainage, in regulation of tumor growth and metastasis. Investigations in human cancers have identified similar TDLN alterations. The lymphatic vasculature of human LNs is somewhat distinct from that of rodent LNs [91], with a thicker capsule surrounding the human cortical (marginal) and medullary sinuses [92]. The lymphatic vasculature of normal versus tumor-draining human or murine LNs has not been investigated much, so that it is difficult to predict how their structure and lymph drainage functions compare. Nonetheless, TDLN lymphatic sinus growth has recently been identified in several types of human cancers, including melanoma and breast, oral, and rectal cancers (Table 2). Interestingly, the growth of TDLN lymphatic sinuses correlates with poor prognosis and metastasis in several types of cancer (Table 2). Further investigation of TDLN lymphatic sinus growth characteristics could identify additional criteria for cancer diagnosis. LN lymphangiogenesis is also not restricted to solid tumors in humans, as lymphatic sinus growth has been identified in human non-Hodgkins lymphomas [93].

A few studies have assessed lymph drainage in human cancer patients, using lymphoscintigraphy of subcutaneously injected radiolabelled colloidal nanoparticles. In melanomas [94] and other skin cancers [95] increased lymph flow predicted metastasis in SLNs, suggesting that this parameter could be developed to identify those patients with poor prognosis cancers. These findings suggest that noninvasive imaging to identify changes in tumor lymph drainage could improve diagnosis of metastatic potential.

**CONCLUSIONS AND OUTLOOK**

Studies of TDLNs in mice developing several types of solid tumors or lymphoma identified extensive growth of lymphatic sinuses, which may predict those cancers with metastatic potential. The correlation of TDLN lymphangiogenesis with metastatic potential also suggests that these processes are linked. Observations in a variety of models together provide support for the hypothesis that TDLN lymphatic sinus growth is an essential step in tumor progression to metastasis. [20,23-25]. However, thus far the cells and molecules regulating these processes are not much understood, other than the requirement for B lymphocytes to induce LN lymphatic sinus growth in some models [18,22]. Identification of the mechanisms controlling TDLN lymphangiogenesis will allow direct testing of lymphatic sinus contributions to tumor dissemination.

TDLN hypertrophy and increased lymph flow are characteristic of aggressive tumors, although tumors sometimes can divert or block lymph drainage, particularly after LN metastasis [87,88]. Increased lymph drainage through the expanded medullary sinuses also may be a characteristic of TDLNs, although this has only been demonstrated thus far for murine lymphomas and melanomas [22,67]. Our studies of E-μ-c-myc mice suggest that LN lymphatic sinus growth could directly or indirectly contribute to changes in lymph drainage, by active or passive mechanisms that remain to be identified. The increased lymphatic sinuses in TDLNs could potentially enhance the reinforcement of peripheral tolerance, to suppress anti-tumor immune responses [16]. The increased lymph drainage through the expanded lymphatic sinuses could alternatively promote tumor immune suppression by increasing the interaction of lymphocytes with lymph-derived self and tumor antigens, or by influencing flow-regulated immune cell functions [96]. The increased lymph flow could also physically promote spread of tumor cells to the draining LN and distant organs, to facilitate metastasis. Therapies targeting TDLN lymphangiogenesis and lymph drainage could potentially be developed to impose an anti-tumor TDLN microenvironment to inhibit tumor growth at a distance, and/or to prevent tumor dissemination to TDLNs and distant organs. Finally, the ability of TDLNs to concentrate nanoparticles [49,51] suggests that subcutaneous nanoparticle delivery could be particularly useful to target the first TDLN for vaccination or drug treatment [97,98].

The initial findings from human cancers suggest
that pathology analysis of lymphatic sinuses of TDLNs could provide useful diagnostic assays to identify those cancers at risk of metastasis that could require more aggressive treatment. MRI lymphography analysis of lymph flow through TDLNs shows promise to provide a noninvasive approach to assess the metastatic potential of tumors, in addition to identifying TDLN micrometastases [79,80,99]. Detailed studies of larger patient cohorts will establish whether particular changes in structure and function of the lymphatic sinuses of human TDLNs versus uninvolved LNs will be useful for diagnosis and treatment decisions. Comparison of different types of human cancers will also be required to establish whether these TDLN alterations identify metastatic potential in only some tumor types, or if they are more universally predictive for cancer diagnosis. Going forward, comparative studies of murine and human TDLN sinus structure and function should help to identify the critical alterations regulating tumor growth and metastasis.

Acknowledgments: We thank Bryan Turnbull, Kendra Byrd, and Monica Montgomery for their assistance.

REFERENCES

25. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in


